Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.

Details

Language :

English

ISSN :

22221751

Volume :

13

Issue :

1

Database :

Complementary Index

Journal :

Emerging Microbes & Infections

Publication Type :

Academic Journal

Accession number :

177810554

Full Text :

https://doi.org/10.1080/22221751.2023.2284297